Key Highlights
● Topline ALTITUDE-AD data for sabirnetug are expected in late 2026.
● The study compares 35 mg/kg and 50 mg/kg doses against placebo over 18 months.
● Cash of US$110.2 million is expected to fund activities into early 2027.
● Six-month net loss was US$53.5 million, compared with US$69.7 million a year earlier.
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) is a clinical-stage biotechnology company whose common stock trades on the Nasdaq under the symbol ABOS. In its second-quarter 2026 results, published on 12 August 2026, the company said topline data from its Phase 2 ALTITUDE-AD study of sabirnetug (also known as ACU193) in early Alzheimer's disease are expected in late 2026.
What the ALTITUDE-AD study involves
According to the company, the trial enrolled 542 participants, with 180 in each of the treatment cohorts. It compares two intravenous doses of sabirnetug, 35 mg/kg and 50 mg/kg, given every four weeks, against placebo over 18 months. The primary endpoint is the integrated Alzheimer's Disease Rating Scale (iADRS). Key secondary endpoints include the Clinical Dementia Rating Sum of Boxes (CDR-SB) and rates of amyloid-related imaging abnormalities (ARIA), a known safety consideration for antibodies in this field. Sabirnetug holds Fast Track designation from the US Food and Drug Administration.
The company also says it is investigating a subcutaneous formulation using Halozyme's ENHANZE technology, which could in principle ease administration if it advances. That remains an early-stage ambition rather than a demonstrated result.
Financial position
All figures are historical and in US dollars. Cash, cash equivalents and marketable securities were US$110.2 million at 30 June 2026, down from US$128.4 million at 31 March 2026. Management expects this to fund current clinical and operational activities into early 2027.
For the quarter ended 30 June 2026, research and development expenses were US$27.8 million, compared with US$37.1 million a year earlier; the company attributed the fall mainly to lower manufacturing, materials and contract research costs linked to ALTITUDE-AD. General and administrative expenses were US$4.7 million, against US$4.6 million. The net loss was US$32.7 million, or US$0.45 per share, versus US$41.0 million, or US$0.68 per share. For the six months ended 30 June 2026, the net loss was US$53.5 million compared with US$69.7 million, and research and development expenses were US$44.3 million against US$62.4 million, a decline consistent with lower trial-related costs.
Pipeline beyond sabirnetug
Acumen is also developing Enhanced Brain Delivery candidates under a licence with JCR Pharmaceuticals. In June 2026 it nominated two candidates, ACU301 and ACU401. At the AAIC conference in July 2026 the company reported that ACU401 showed up to 40-fold greater frontal cortex exposure in non-human primates, with no haematological safety signals observed. An investigational new drug filing for a lead candidate is targeted for mid-2027. Animal findings do not guarantee similar results in people.
Why it matters
The late-2026 readout is the central event for the company. The study will show whether the antibody slows clinical decline in early Alzheimer's disease and what its ARIA profile looks like. Two dose arms against placebo permit a dose comparison, though outcomes cannot be assumed. Because the stated cash runway reaches only into early 2027, the timing of the data and any subsequent financing or partnering decisions are closely linked.
A Late-2026 Window With No Exact Date and High Trial Risk
Clinical trials can fail, and many Alzheimer's candidates have historically disappointed investors and clinicians. Topline timing is a management expectation that may change. The release does not specify an exact date for the topline announcement, only the "late 2026" window.






Please wait processing your request...